Lipigon Pharmaceuticals AB (LPGO) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.552x

Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) has a cash flow conversion efficiency ratio of -0.552x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.32 Million ≈ $-895.90K USD) by net assets (Skr15.09 Million ≈ $1.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Lipigon Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2018–2024)

This chart illustrates how Lipigon Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Lipigon Pharmaceuticals AB for a breakdown of total debt and financial obligations.

Lipigon Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lipigon Pharmaceuticals AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Kingswood Holdings Ltd LSE:KWG	0.051x
SysGroup PLC LSE:SYS	-0.014x
Lexington Gold Ltd LSE:LEX	0.000x
LMS Capital Plc LSE:LMS	-0.042x
OPG Power Venture Plc LSE:OPG	0.037x
TRELLUS HEALTH LS -0006 F:85Q	N/A
aReit Prop Ltd JSE:APO	0.000x
Cordel Group PLC LSE:CRDL	-0.209x

Annual Cash Flow Conversion Efficiency for Lipigon Pharmaceuticals AB (2018–2024)

The table below shows the annual cash flow conversion efficiency of Lipigon Pharmaceuticals AB from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Lipigon Pharmaceuticals AB stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr7.76 Million ≈ $835.21K	Skr-24.78 Million ≈ $-2.67 Million	-3.193x	-534.28%
2023-12-31	Skr28.44 Million ≈ $3.06 Million	Skr-14.32 Million ≈ $-1.54 Million	-0.503x	+94.80%
2022-12-31	Skr3.87 Million ≈ $416.58K	Skr-37.47 Million ≈ $-4.03 Million	-9.679x	-529.59%
2021-12-31	Skr22.96 Million ≈ $2.47 Million	Skr-35.30 Million ≈ $-3.80 Million	-1.537x	-131.41%
2020-12-31	Skr12.98 Million ≈ $1.40 Million	Skr-8.62 Million ≈ $-928.19K	-0.664x	+74.08%
2019-12-31	Skr2.17 Million ≈ $233.42K	Skr-5.56 Million ≈ $-598.24K	-2.563x	-166.14%
2018-12-31	Skr-842.00K ≈ $-90.61K	Skr-3.26 Million ≈ $-351.15K	3.875x	--

About Lipigon Pharmaceuticals AB

ST:LPGO Sweden Biotechnology

Market Cap

$163.02K

Skr1.51 Million SEK

Market Cap Rank

#30868 Global

#735 in Sweden

Share Price

Skr0.00

Change (1 day)

-13.79%

52-Week Range

Skr0.00 - Skr0.19

All Time High

Skr10.15